Press Releases


>£2m contract extension win in Huntington's disease

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, has executed a c. £2m contract to provide additional imaging services that will support a pivotal Huntington's disease (HD) study. This builds on the Company's existing contract to support our 'top-20' pharma client's Phase III study in HD.

Read more

IXICO joins the TRACK-FA Neuroimaging Consortium to develop novel imaging markers in Friedreich's Ataxia

IXICO plc announces that it has entered into a 5 year collaboration with the Friedreich's Ataxia Research Alliance (FARA), a non-profit organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreich's Ataxia (FA).

Read more

Global Alzheimer's Platform Foundation selects IXICO for innovative Bio-Hermes trial

IXICO plc, the data analytics company delivering insights in neuroscience, announces that it has been selected by the Global Alzheimer's Platform Foundation® (GAP) to support GAP's planned Bio-Hermes trial.

Read more

Trading Update: Profitability for full year 2020 expected to be ahead of market expectations

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that, despite COVID-19, it is achieving stronger than anticipated growth across the second half of the year.   The Company is benefiting from continued operational leverage, generated by revenue growth and investments made to drive scale and efficiency.

Read more

Investor Presentation: 25th August

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it will provide a live presentation presented by CEO, Giulio Cerroni and CFO, Grant Nash, on Tuesday 25 August at 1. 30pm.

Read more

IXICO to present at the On Helix Digital conference

IXICO plc announces the Company’s digital attendance at the On Helix Digital conference, on the 13-14 July 2020. IXICO will share a pre-recorded presentation by Robin Wolz, SVP Science & Innovation, titled ‘Biomarkers for CNS clinical trials from imaging and actigraphy.

Read more

Expected strengthening FY20 financial performance of at least £9.1m revenues, £0.9m EBITDA and positive operating cash

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces a trading update, confirming that the impact of COVID-19 has been modest and that IXICO expects to maintain double-digit revenue growth across FY21.

Read more

Half yearly report to 31 March 2020

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces its unaudited interim results for the six months ended 31 March 2020. Financial highlights: ·    Reported revenues of £4. 6 million; 33. 0% growth on H1 2019 (2019: £3. 4 million) ·    Strong gross margin at 66. 5% (2019: 66.

Read more

33-40 of 63 results